Whole Body MR and Low Dose CT In Myeloma: A Pictorial of Imaging Findings

Congress:

ECR 2020

Poster Number:

C-08521

Type:

Educational Exhibit

Keywords:

Cancer, Blood, Imaging sequences, MR-Diffusion/Perfusion, CT, Oncology, Musculoskeletal bone, Haematologic, Musculoskeletal, Retrospective, Observational, Performed at one institution

Authors:

M. V. Raciti¹, G. Savietto², A. Maggi², M. Zacchino², E. M. Bassi², F. Calliada², L. Preda²; ¹Pavia, IT/IT, ²Pavia/IT

DOI:

10.26044/ecr2020/C-08521

DOI-Link:

https://dx.doi.org/10.26044/ecr2020/C-08521

Background

The high sensibility of WB-MR (including Diffusion Weighted Imaging) for bone marrow imaging and viability evaluation led this technique to an increasing role in the assessment of MM in each stage of disease.

WB-MR is now included into international standards for imaging patients with MM e.g. NICE guidelines (which suggests the use of WB-MR as first line imaging in Patients with a suspected diagnosis of MM) or British Society for Haematology (which recommends WB-MR for monitoring response of nonsecretory or oligosecretory myeloma).

WB-MR, however, is not widely diffuse, therefore, LD-CT is often used as a first-line imaging technique.